Inotrem SA raises 39m to provide POC for nangibotide
French biotech Inotrem SA raised 39m to finance Phase IIb efficacy testing of its TREM1 blocker nangibotide (Motrem) in patients with septic shock.
Ermium Therapeutics bags 6.3m in Series A round
Paris-based Ermium Therapeutics has completed a Series A financing to develop breakthrough auto-immune therapeutics.
Pharvaris BV raises $66m to advance oral HAE drug
Leiden-based Pharvaris BV received a cash injection that will be used to push PHA121, the very first orally administered hereditary angioedema (HAE) drug.
4BIO Ventures launches US$50m fund
London and Boston-based 4BIO Ventures has raised US$50m to target early-stage developers of advanced therapies by means of its new 4Bio Ventures II fund.
ADC Therapeutics set to go public
Antibody drug conjugate expert ADC Therapeutics SA has filed a Registration Statement for an Initial Public Offering with the US Securities and Exchange Commission.
iStar Medical SA raises 40.1m
Glucoma transplant specialist iStar Medical SA has closed a Series C finanincing round led by LSP and Gimv.
UniQure looking to raise US$200m
Dutch gene therapy company UniQure has launched a US$200m stock offering on Nasdaq.
MS: Polpharma joins forces with Sandoz
Polpharma Biologics SA has partnered up with Novartis subsidiary Sandoz AG to market a natalizumab biosimilar. As part of the global commercialization agreement, Polpharma Biologics will be responsible for the development, manufacturing and supply of the collaboration biosimilar, which is currently in Phase III clinical development for the treatment of relapsing-remitting multiple sclerosis (RRMS).
Pro-apoptotic protein blocks autoimmunity
A US-EU research team has found that a class of compounds that promote tumour cell death can also limit autoimmunity.
Sequencing-ready DNA for fast Molecular Breeding results
BioEcho develops single-spin and 96-well kits for the isolation of DNA from different starting materials. Their proprietary EchoLUTION single-step technology avoids the use of inhibitory process reagents while using dedicated efficient lysis reagents for e.g. different plant tissues. In contrast to common bind-wash-elute procedures, the process does not require washing steps. The inhibitor-free DNA enables lowered time-to-result in enzyme-dependent genomic analyses such as PCR or NGS.